BPC-157 vs Larazotide
Reviewed by the BestHealingPeptides Editorial Team ·
BPC-157 and larazotide both have gut-healing applications but operate at completely different points in mucosal biology. BPC-157 supports mucosal angiogenesis and ulcer healing through a broad pro-regenerative profile; larazotide blocks zonulin-driven tight-junction disassembly to prevent paracellular antigen leak. The two can be studied independently or in combination for layered gut-barrier research.
BPC-157
A 15-amino-acid pentadecapeptide derived from a protective protein found in human gastric juice. The most-studied healing research peptide, with extensive pre-clinical work on tendon, ligament, gut, and vascular repair.
Larazotide
An eight-amino-acid synthetic peptide functioning as a tight-junction regulator and zonulin antagonist. Designed for luminal delivery with minimal systemic absorption, larazotide has been investigated in multiple Phase II trials for coeliac disease with persistent symptoms, and represents the furthest-advanced clinical programme for a peptide targeting intestinal barrier function.
| Aspect | BPC-157 | Larazotide |
|---|---|---|
| Size | 15 amino acids (1,419 Da) | 8 amino acids (727 Da) |
| Mechanism breadth | Multi-pathway: angiogenesis, NO, GH-receptor, neurotransmitter axes | Single-target: zonulin-receptor antagonism at apical tight junction |
| Strongest endpoint | Mucosal regeneration, anastomotic healing | Intestinal permeability (lactulose/mannitol) |
| Clinical evidence | Pre-clinical only | Phase IIb coeliac disease (Leffler 2015) |
| Delivery route | SC, IP, oral (rodent); IV, IM (research) | Oral capsule (clinical-trial route) |
| WADA status | S0 (non-approved substances) | Not listed |
Mechanism — different layers of gut biology
BPC-157 acts broadly on mucosal repair: VEGFR2-Akt-eNOS angiogenesis at the ulcer base, nitric-oxide-system stabilisation against ischaemia-reperfusion, growth-hormone-receptor upregulation in mucosal fibroblasts, and effects on the dopamine-serotonin-GABA axes that influence gut motility. Its mechanism is integrative rather than receptor-defined. Larazotide acts at a single defined molecular target — the zonulin-receptor signalling complex on the apical surface of intestinal epithelial cells — and prevents tight-junction disassembly, limiting paracellular passage of luminal antigens. The two peptides therefore intervene at distinct biological layers: regenerative repair of damaged mucosa (BPC-157) versus prevention of barrier failure (larazotide).
Evidence pathways — pre-clinical vs clinical
BPC-157 has the deeper and broader pre-clinical evidence base, with extensive published work covering oesophagitis, gastric ulcer, colitis, anastomotic healing, and toxicity-protection models — almost entirely produced by the Sikiric Zagreb group with some independent replication. No human controlled trials have been published. Larazotide has the deeper clinical evidence base — multiple Phase I and Phase II trials in coeliac disease, including a 342-subject Phase IIb (Leffler 2015) showing significant symptom reduction. The two compounds therefore sit at opposite ends of the pre-clinical-to-clinical spectrum: BPC-157 is pre-clinical-dominated; larazotide is clinical-development-advanced.
Delivery — both face oral challenges differently
BPC-157 has reported oral activity in rodent models attributed to gastric-mucus binding and resistance to gastric acidity, but oral pharmacokinetic data in humans are absent. Subcutaneous and intraperitoneal routes are the standard research administration paths. Larazotide is engineered for oral luminal action with minimal systemic absorption — capsule delivery is the clinical-trial route and the principal practical advantage of the compound over systemically absorbed alternatives.
Safety profile
Both peptides have favourable pre-clinical safety profiles. Larazotide has the most extensive human safety dataset of any research peptide in the gut-barrier space, with adverse-event profiles in Phase IIb comparable to placebo. BPC-157's safety record is pre-clinical only; no controlled human safety studies have been published. The combination has no known pharmacological interaction; both are designed to act at the gut mucosa, larazotide luminally and BPC-157 from either the luminal or vascular side depending on route.
Choosing between them
Choose BPC-157 for research targeting mucosal regeneration, ulcer healing, angiogenesis at the ulcer base, or post-surgical anastomotic healing — its mechanistic profile matches active-repair biology. Choose larazotide for tight-junction and intestinal-permeability research, particularly in coeliac-disease and antigen-translocation models. For combined-mechanism research models — for example, mucosal-inflammation studies that combine barrier disruption with epithelial damage — both can be deployed together to address the prevention and repair axes simultaneously.
Verdict
BPC-157 and larazotide are mechanistically complementary gut peptides operating at different layers of mucosal biology. BPC-157 leads pre-clinical mucosal regeneration; larazotide leads human clinical tight-junction modulation. Choose by which mechanistic layer the research targets — and combine them when the model demands both.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.